17.5: Class IV- Calcium Channel Blockers
By the end of this section, you should be able to:
- 17.5.1 Identify the characteristics of the calcium channel blocker drugs used to treat dysrhythmias.
- 17.5.2 Explain the indications, actions, adverse reactions, and interactions of calcium channel blocker drugs used to treat dysrhythmias.
- 17.5.3 Describe the nursing implications of calcium channel blocker drugs used to treat dysrhythmias.
- 17.5.4 Explain the client education related to calcium channel blocker drugs used to treat dysrhythmias.
Calcium has several roles within cardiac tissue. It flows into the cells of the SA node (the pacemaker of the heart) and AV node to mediate the heart rate and conduct electrical signals from the atria to the ventricles. Calcium also facilitates contraction of the cardiac myocytes when stimulated by the cardiac conduction system. Outside the heart, calcium facilitates arterial vasoconstriction, which in turn maintains blood pressure.
Antidysrhythmic calcium channel blocker s are class IV Vaughan Williams drugs and are also known as nondihydropyridine (non-DHP) calcium channel blockers. They inhibit calcium channels in cardiac cells, resulting in a slower heart rate, slower conduction through the AV node, and a decreased force of contraction. Calcium channel blockers are useful for slowing the heart rate in clients with atrial fibrillation with rapid ventricular response because they slow down the conduction of abnormal impulses through the AV node, thus decreasing the rate at which the ventricles are prompted to contract.
Many calcium channel blockers have drug interactions, which warrant vigilant assessment. Specific drug interactions will be discussed for the agents in the following sections.
Safety Alert
Calcium Channel Blockers
Calcium channel blocker antidysrhythmic drugs reduce heart rate and blood pressure. The nurse must monitor the baseline heart rate and blood pressure before administering a calcium channel blocker and then monitor them frequently during therapy. If the baseline heart rate is less than 60 beats per minute, consider checking with the health care provider before administration.
Another class of calcium channel blockers, the DHP calcium channel blockers, block calcium channels only within arteries, not within the heart. Therefore, DHP calcium channel blockers are useful for treating hypertension but not for treating dysrhythmias. See Antihypertensive and Antianginal Drugs for more information about hypertension treatment.
The most common non-DHP calcium channel blockers are diltiazem and verapamil.
Diltiazem
Diltiazem is a non-DHP calcium channel blocker antidysrhythmic. It is available in both oral and intravenous dosage forms; oral options include immediate-release and extended-release products. It is FDA approved for hypertension and angina. The intravenous form is also FDA approved for heart rate control in atrial fibrillation. Although oral diltiazem is not FDA approved for this condition, national guidelines do recommend its use for this indication (January et al., 2014).
Many different companies manufacture oral diltiazem as similar but not bioequivalent generic products, which can lead to confusion during prescribing and administration. Some examples are Cardizem, Cartia XT, Dilt-XR, Taztia XT, Tiadylt ER, and Matzim LA. The nurse should take an accurate medication history with the specific medication the client takes and be careful to avoid confusing the various products.
Diltiazem has a notable drug interaction with simvastatin. The FDA recommends limiting the dose of simvastatin to 10 mg daily with concomitant use because it can result in increased plasma levels of simvastatin, leading to adverse events (Hopewell et al., 2020; U.S. Food and Drug Administration, 2017).
Verapamil
Verapamil is a non-DHP calcium channel blocker approved for the treatment of angina, atrial fibrillation/atrial flutter, hypertension, and supraventricular tachycardia. It is available in both oral and intravenous dosage forms. As with diltiazem, the FDA recommends limiting the dose of simvastatin to 10 mg daily with concomitant use because it can result in increased plasma levels of simvastatin, leading to adverse events (Hopewell et al., 2020; U.S. Food and Drug Administration, 2017).
Table 17.9 lists common calcium channel blockers and typical routes and dosing for adult clients.
| Drug | Routes and Dosage Ranges |
|---|---|
|
Diltiazem
( Cardizem , Cartia XT , Dilt XR , Taztia XT , Tiazac ) |
Atrial fibrillation:
Extended-release: 120–360 mg orally daily. IV: 0.25 mg/kg IV bolus over 2 minutes, then 5–15 mg/hour continuous IV infusion. |
|
Verapamil
( Calan SR ) |
Atrial fibrillation: 0.075–0.15 mg/kg IV bolus over 2 minutes, then 0.005 mg/kg/min continuous IV infusion. |
Adverse Effects and Contraindications
Calcium channel blockers can cause bradycardia as an extension of their therapeutic effect. They also decrease arterial vasoconstriction, which reduces blood pressure and can cause hypotension. Additionally, they can cause swelling and edema.
Because calcium is important for facilitating ventricular contraction, calcium channel blockers can decrease contractility of the heart. This can be particularly troublesome in clients with heart failure with reduced ejection fraction or acute myocardial infarction, who already have decreased contractility. For this reason, non-DHP calcium channel blockers should be used cautiously or avoided in those clients. They should also be avoided in clients who have bradycardia or AV blocks without a pacemaker or those receiving beta-adrenergic blockers.
Table 17.10 is a drug prototype table for calcium channel blockers featuring diltiazem. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.
|
Drug Class
Nondihydropyridine calcium channel blocker Mechanism of Action Inhibits the calcium channel in cardiac tissue and blood vessels, leading to decreased conduction through the atrioventricular node and vasodilation |
Drug Dosage
Atrial fibrillation: Extended release: 120–360 mg orally daily. IV: 0.25 mg/kg IV bolus over 2 minutes, then 5–15 mg/hour continuous IV infusion. |
|
Indications
Angina Hypertension Atrial fibrillation/flutter Therapeutic Effects Decreases heart rate Lowers blood pressure |
Drug Interactions
Substrates or inhibitors of CYP3A4 Beta-adrenergic blockers Benzodiazepines Anesthetics Clonidine Cyclosporine Digoxin Ivabradine Quinidine Rifampin Statins Food Interactions Alcohol Grapefruit juice |
|
Adverse Effects
Headache Dizziness Bradycardia Atrioventricular block Edema Asthenia Rash, including Stevens–Johnson syndrome |
Contraindications
Hypersensitivity Sick sinus syndrome (unless client has ventricular pacemaker) Hypotension Myocardial infarction Pulmonary congestion |
Nursing Implications
The nurse should do the following for clients who are taking calcium channel blockers:
- Obtain a complete medication list to check for any drug interactions.
- Measure heart rate and blood pressure before administering a non-DHP calcium channel blocker.
- Notify the health care provider if the client has baseline bradycardia and does not have a pacemaker.
- Use continuous cardiac/hemodynamic monitoring in clients on intravenous calcium channel blockers.
- Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.
Client Teaching Guidelines
The client taking a calcium channel blocker should:
- Contact their health care provider if they experience signs or symptoms of therapeutic failure, such as racing heart, lightheadedness, or fatigue (signs and symptoms of the dysrhythmia).
- Contact their health care provider if they experience signs or symptoms of adverse effects of the medication, such as dizziness or lightheadedness (which could indicate hypotension) or edema.
- Avoid drinking grapefruit juice.
- Keep an accurate and up-to-date medication list and provide it to their providers at each appointment in order to avoid drug interactions.
- Monitor their heart rate and blood pressure as directed by their health care provider.